Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.61 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | PNLIP | P16233 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6516221 | 0.92 | KMT2A (0.73) | TDP1KMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL61417 | 0.88 | TDP1 (1.00) | TDP1KMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL27903080 | 0.87 | MEN1 (0.62) | TDP1KMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL18826484 | 0.86 | KMT2A (0.66) | TDP1KMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL14192610 | 0.85 | KMT2A (0.63) | TDP1KMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL171438 | 0.85 | HPGD (0.71) | KMT2AMEN1SMN1; SMN2ALDH1A1MTNR1A | |
| SCHEMBL14384396 | 0.85 | MTNR1A (0.76) | TDP1KMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL2844063 | 0.85 | KMT2A (0.77) | TDP1KMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL14384846 | 0.83 | MTNR1A (0.64) | TDP1KMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3547563 | 0.83 | PKM (0.62) | TDP1KMT2AMEN1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230350305-A1 | MANUFACTURING METHOD FOR CURED SUBSTANCE, MANUFACTURING METHOD FOR LAMINATE, AND MANUFACTURING METHOD FOR SEMICONDUCTOR DEVICE, AND TREATMENT LIQUID | FUJIFILM CORPORATION (JP) | 2023-11-02 | — | — | US | disclosed |
| US-10759765-B2 | Heterocyclic carboxylic acid amide ligand and applications thereof in copper catalyzed coupling reaction of aryl halogeno substitute | CE PHARM CO., LTD. (CN) | 2020-09-01 | — | — | US | disclosed |
| US-20190127337-A1 | HETEROCYCLIC CARBOXYLIC ACID AMIDE LIGAND AND APPLICATIONS THEREOF IN COPPER CATALYZED COUPLING REACTION OF ARYL HALOGENO SUBSTITUTE | CE PHARM CO., LTD. (CN) | 2019-05-02 | — | — | US | disclosed |
| US-20180207628-A1 | OXALIC ACID MONOAMIDE LIGAND, AND USES THEREOF IN COUPLING REACTION OF COPPER-CATALYZED ARYL HALOGEN SUBSTITUTE | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2018-07-26 | — | — | US | disclosed |
| WO-2017177979-A1 | HETEROCYCLIC CARBOXYLIC ACID AMIDE LIGAND AND APPLICATIONS THEREOF IN COPPER CATALYZED COUPLING REACTION OF ARYL HALOGENO SUBSTITUTE | 中国科学院上海有机化学研究所 | 2017-10-19 | — | — | WO | disclosed |
| WO-2017012379-A1 | OXALIC ACID MONOAMIDE LIGAND, AND USES THEREOF IN COUPLING REACTION OF COPPER-CATALYZED ARYL HALOGEN SUBSTITUTE | 中国科学院上海有机化学研究所 | 2017-01-26 | — | — | WO | disclosed |
| EP-1606108-B1 | DOUBLE-SIDED METALLIC LAMINATE AND METHOD FOR MANUFACTURING THE SAME | LG CHEMICAL LTD (KR) | 2015-08-19 | — | — | EP | disclosed |
| WO-2015021943-A1 | INDUCING NEUROGENESIS BY AXIN ENHANCER | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2015-02-19 | — | — | WO | disclosed |
| CN-102060790-B | Quinoxaline double N-oxide derivative ligand and application thereof in promotion on copper-catalyzed C-O coupling reaction | SHANGHAI INST TECHNOLOGY | 2013-01-09 | — | — | CN | disclosed |
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | DUMAS JACQUES (US) | 2012-06-14 | — | — | US | disclosed |
| US-7285552-B2 | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient | ONO PHARMACEUTICALS CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20070042202-A1 | Double-sided metallic laminate and method for manufacturing the same | LG CHEM, LTD. (KR) | 2007-02-22 | — | — | US | disclosed |
| US-7119091-B2 | Triazaspiro[5.5]undecane derivatives and pharmaceutical compositions comprising thereof, as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-10-10 | — | — | US | disclosed |
| US-20060019977-A1 | Spiroheterocyclic derivative compounds and drugs comprising the compound as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1553098-A1 | SPIROHETEROCYCLIC DERIVATIVE COMPOUNDS AND DRUGS COMPRISING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
| EP-1236726-B1 | TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040106619-A1 | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient | ONO PHARMACEUTICALS CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| US-20040097511-A1 | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | PANASONIC CORPORATION (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1378509-A1 | DRUGS CONTAINING TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-01-07 | — | — | EP | disclosed |
| EP-1236726-A1 | TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | MAPK1, MAP3K1, MAP3K7 | TDP1 1729/4885KMT2A 2201/4885MEN1 3545/4885 |
| US-20040106619-A1 | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient | NONO, NAA15, USO1 | TDP1 2295/4885KMT2A 2233/4885MEN1 4685/4885 |
| US-20190127337-A1 | HETEROCYCLIC CARBOXYLIC ACID AMIDE LIGAND AND APPLICATIONS THEREOF IN COPPER CATALYZED COUPLING REACTION OF ARYL HALOGENO SUBSTITUTE | AOC1, AOC2, AOC3 | TDP1 4832/4885KMT2A 1850/4885MEN1 3912/4885 |
| US-20060019977-A1 | Spiroheterocyclic derivative compounds and drugs comprising the compound as the active ingredient | CCR1, ACKR3, CCR10 | TDP1 4696/4885KMT2A 2776/4885MEN1 4518/4885 |
| US-20040097511-A1 | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | CXCR5, CCL11, ACKR3 | TDP1 3491/4885KMT2A 4140/4885MEN1 4863/4885 |
| US-10759765-B2 | Heterocyclic carboxylic acid amide ligand and applications thereof in copper catalyzed coupling reaction of aryl halogeno substitute | AOC1, AOC2, AOC3 | TDP1 4832/4885KMT2A 1850/4885MEN1 3912/4885 |
| US-20180207628-A1 | OXALIC ACID MONOAMIDE LIGAND, AND USES THEREOF IN COUPLING REACTION OF COPPER-CATALYZED ARYL HALOGEN SUBSTITUTE | AOC2, AOC1, AOC3 | TDP1 4699/4885KMT2A 1774/4885MEN1 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.